CNCR vs. WDNA

Last updated Jun 24, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and WDNA (WisdomTree BioRevolution Fund) are both Health & Biotech Equities funds - CNCR tracks the Loncar Cancer Immunotherapy Index while WDNA tracks the WisdomTree BioRevolution Index. Both are passively managed. CNCR charges 0.79%/yr vs 0.45%/yr for WDNA.

Performance

CNCR vs. WDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and WisdomTree BioRevolution Fund (WDNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

WDNA

• 1D: 0.49%
• 1M: 8.93%
• YTD: 13.32%
• 6M: 11.11%
• 1Y: 50.90%
• 3Y*: 5.47%
• 5Y*: -5.03%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. WDNA - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
WDNA WisdomTree BioRevolution Fund	10.75%

CNCR vs. WDNA - Sectors Allocation Comparison

Sectors	CNCR	WDNA
Healthcare	96.6%	85.0%
Financial Services	3.3%	-
Basic Materials	-	6.5%
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	3.0%
Energy	-	1.1%
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

CNCR vs. WDNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CNCR

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

WDNA

WDNA Risk / Return Rank: 66
WDNA Sharpe Ratio Rank: 65
WDNA Sortino Ratio Rank: 66
WDNA Omega Ratio Rank: 56
WDNA Calmar Ratio Rank: 85
WDNA Martin Ratio Rank: 59

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. WDNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and WisdomTree BioRevolution Fund (WDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	CNCR	WDNA	Difference
Sharpe ratio: Return per unit of total volatility	—	1.98	—
Sortino ratio: Return per unit of downside risk	—	2.81	—
Omega ratio: Gain probability vs. loss probability	—	1.32	—
Calmar ratio: Return relative to maximum drawdown	—	4.37	—
Martin ratio: Return relative to average drawdown	—	9.80	—

Drawdowns

CNCR vs. WDNA - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum WDNA drawdown of -58.87%. Use the drawdown chart below to compare losses from any high point for CNCR and WDNA.

Drawdown Indicators

	CNCR	WDNA	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-58.87%	+58.87%
Max Drawdown (1Y) Largest decline over 1 year	—	-11.70%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-38.25%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-58.87%	—
Current Drawdown Current decline from peak	0.00%	-27.05%	+27.05%
Average Drawdown Average peak-to-trough decline	0.00%	-35.56%	+35.56%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	5.21%	—

Volatility

Volatility by Period

	CNCR	WDNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	7.39%	—
Volatility (6M) Calculated over the trailing 6-month period	—	16.98%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	25.90%	-25.90%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	25.14%	-25.14%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	25.06%	-25.06%

CNCR vs. WDNA - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than WDNA's 0.45% expense ratio.

Dividends

CNCR vs. WDNA - Dividend Comparison

CNCR has not paid dividends to shareholders, while WDNA's dividend yield for the trailing twelve months is around 4.03%.

Position	TTM	2025	2024	2023	2022	2021
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
WDNA WisdomTree BioRevolution Fund	4.03%	4.57%	0.75%	0.80%	0.38%	0.10%

Frequently Asked Questions

Which ETF is better, CNCR or WDNA?

On fees, WDNA is cheaper at 0.45% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or WDNA?

WDNA is cheaper with a 0.45% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, CNCR or WDNA?

WDNA has the higher dividend yield at 4.03%, compared with 0.00% for CNCR.

What is the main difference between CNCR and WDNA?

CNCR tracks Loncar Cancer Immunotherapy Index, while WDNA tracks WisdomTree BioRevolution Index. They also come from different issuers: Exchange Traded Concepts and WisdomTree. Their fees differ too: 0.79% for CNCR and 0.45% for WDNA.